A Study of Niacin Regulation

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Excessive Weight Gain
Interventions
DRUG

Niacin

Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion

Trial Locations (1)

55904

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER

NCT06175403 - A Study of Niacin Regulation | Biotech Hunter | Biotech Hunter